NCT00111813View on ClinicalTrials.gov

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

May 31, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

vorinostat

Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

DRUG

bortezomib

Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00111813 - Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | Biotech Hunter | Biotech Hunter